Crofelemer, a purified proanthocyanidin oligomer extracted from the bark latex of Croton lechleri, is in clinical trials for secretory diarrheas of various etiologies. We investigated the antisecretory mechanism of crofelemer by determination of its effect on the major apical membrane transport and signaling processes involved in intestinal fluid transport. Using cell lines and measurement procedures to isolate effects on individual membrane transport proteins, crofelemer at 50 µM had little or no effect on the activity of epithelial Na + or K + channels, or on cAMP or calcium signaling. Crofelemer inhibited the cystic fibrosis transmembrane regulator (CFTR) Cl -channel with maximum inhibition of ~60 % and an IC 50 ~7 µM. Crofelemer action at an extracellular site on CFTR produced voltage-independent block with stabilization of the channel closed state. Crofelemer did not affect the potency of glycine hydrazide or thiazolidionone CFTR inhibitors. Crofelemer action resisted washout, with <50 % reversal of CFTR inhibition after 4 hours. Crofelemer was also found to strongly inhibit the intestinal calcium-activated Cl -channel TMEM16A by a voltage-independent inhibition mechanism with maximum inhibition >90 % and IC 50 ~6.5 µM. The dual inhibitory action of crofelemer on two structurally unrelated pro-secretory intestinal Cl -channels may account for its intestinal antisecretory activity.
and measurement procedures to isolate effects on individual membrane transport proteins, crofelemer at 50 µM had little or no effect on the activity of epithelial Na + or K + channels, or on cAMP or calcium signaling. Crofelemer inhibited the cystic fibrosis transmembrane regulator (CFTR) Cl -channel with maximum inhibition of ~60 % and an IC 50 ~7 µM. Crofelemer action at an extracellular site on CFTR produced voltage-independent block with stabilization of the channel closed state. Crofelemer did not affect the potency of glycine hydrazide or thiazolidionone CFTR inhibitors. Crofelemer action resisted washout, with <50 % reversal of CFTR inhibition after 4 hours. Crofelemer was also found to strongly inhibit the intestinal calcium-activated Cl -channel TMEM16A by a voltage-independent inhibition mechanism with maximum inhibition >90 % and IC 50 ~6.5 µM. The dual inhibitory action of crofelemer on two structurally unrelated pro-secretory intestinal Cl -channels may account for its intestinal antisecretory activity.
This article has not been copyedited and formatted. The final version may differ from this version. 
INTRODUCTION
Secretory diarrhea remains a global health challenge in developing and developed countries.
Intestinal fluid secretion involves Cl -influx into enterocytes though a Na + /K + /2Cl -symporter on the basolateral membrane, and Cl -efflux through apical (lumen-facing) Cl -channels (Barrett and Keely, 2000; Field, 2003; Thiagarajah and Verkman, 2005) and Escherichia coli elevate cyclic nucleotide concentrations in enterocytes, resulting in Cl -channel activation and fluid secretion. Na + absorption through apical membrane Na + channels and electrogenic Na + -coupled symporters oppose net fluid secretion. The rate of net intestinal fluid secretion, and hence the severity of secretory diarrhea, is expected to be sensitive to modulators of these transporting systems and to upstream cyclic nucleotide or calcium signaling pathways.
Treatment of secretory diarrheas in developing countries is primarily supportive, involving replacement of intestinal fluid losses using oral rehydration salt (ORS) solution. Though ORS has greatly improved clinical outcome in cholera and other diarrheas, there remains significant mortality from infectious diarrheas, with recurrent major outbreaks. Potential targets for diarrhea therapy to further reduce morbidity and mortality include the bacteria itself (vaccines, antimicrobials), elaborated enterotoxins and their cellular uptake, cellular cyclic nucleotide signaling, and the pro-secretory membrane transporters mentioned above (reviewed in Field, 2003; Thiagarajah and Verkman, 2005) . Our laboratory has focused on targeted inhibitors of the two principal apical membrane Cl -channels in enterocytes, the cystic fibrosis transmembrane regulator conductance (CFTR), a cAMP-stimulated Cl -channel, and calcium-activated Cl -channels (CaCCs). By high-throughput screening and follow-up chemistry, we identified inhibitors of these This article has not been copyedited and formatted. The final version may differ from this version. Cl -channels, including nanomolar-potency thiazolidinone (Ma et al., 2002) , glycine hydrazide (Muanprasat et al., 2004) and pyrimido-pyrrolo-quinoxalinedione (Tradtrantip et al., 2009a ) CFTR inhibitors, and 3-acyl-2-aminothiophene CaCC inhibitors (de la Fuente et al., 2008) . We have also identified thiophenecarboxylate activators of phosphodiesterases that reduce cyclic nucleotide concentrations and toxin-induced intestinal fluid secretion (Tradtrantip et al., 2009b) .
Here, we investigate the antisecretory mechanism of crofelemer, a purified proanthocyanidin oligomer extracted from the blood-red bark latex of the South American medicinal plant Croton lechleri (dragon's blood). The sap of C. lechleri has been used in South
American countries like Ecuador and Peru for many years to treat diarrheas, including dysentery and cholera, as well as various lung, stomach and other conditions (Ubillas et al., 1994; Jones, 2003; Risco et al., 2003; Rossie et al., 2003) . Additional pharmacological studies have shown that crofelemer reduced fluid secretion in cell culture and mouse models (Gabriel et al., 1999) .
Crofelemer is currently in clinical trials for therapy of secretory diarrheas associated with acute infections including cholera, as well as chronic diarrhea associated with HIV/AIDS and diarrheapredominant irritable bowel syndrome (Holodniy et al., 1999; DiCesare et al., 2002; Mangel and Chaturvedi, 2008) . Here, we report that the antisecretory mechanism-of-action of crofelemer involves inhibition of both CFTR and CaCC Cl -channels at the luminal membrane of enterocytes.
MATERIALS AND METHODS

Chemicals
Forskolin, apigenin and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Sigma. synthesized as reported (Ma et al., 2002; Muanprasat et al., 2004; de la Fuente et al., 2008) .
Crofelemer was provided by Napo Pharmaceuticals Inc. (South San Francisco, CA). Crofelemer was prepared by extraction from the bark latex of C. lechleri. After chilling the bark latex to induce a phase separation the solid residues were discarded and the supernatant was extracted with butanol. The crofelemer-containing aqueous phase was filtered by tangential flow and subjected to low pressure liquid chromatography on an ion exchange column. The crofelemer-enriched fraction was purified on a Sephadex column, and crofelemer was eluted using a mobile phase of aqueous acetone. Crofelemer was then dried under vacuum. Crofelemer is a proanthocyanidin oligomer with an average molecular weight of 2100 daltons, in agreement with a previously reported average molecular weight of 2300 daltons (Ubillas et al., 1994) . Fig. 2A shows the putative structure of crofelemer. The material used for the studies here is the same as that used in clinical trials, where it is formulated for oral dosing as modified-release tablets (125 or 250 mg crofelemer per tablet).
Cell culture
Fisher rat thyroid (FRT) cells expressing human CFTR were generated as described (Ma et al., 2002) . FRT cells expressing human TMEM16A (cDNA provided by Dr. Luis Galietta, Gaslini
Institute, Genoa, Italy) were generated similarly. FRT cells were cultured in F-12 Modified Coon's Medium (Sigma) supplemented with 10% fetal bovine serum (Hyclone), 2 mM glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 350 µg/ml hygromycin and 500 µg/ml geneticin.
Primary cultures of human bronchial epithelial cells were maintained at an air-liquid interface as described (Yamaya et al., 1992) . T84 cells were cultured in DMEM/Ham's F-12 (1:1) medium
This article has not been copyedited and formatted. The final version may differ from this version. between 3 and 10 Gohm. After establishing the whole-cell configuration, CFTR was activated by forskolin and IBMX, and TMEM16A by ATP. Whole-cell currents were elicited by applying hyperpolarizing and depolarizing voltage pulses from a holding potential of 0 mV to potentials between -100 mV and +100 mV in steps of 20 mV. The current output was filtered at 5 kHz.
Currents were digitized and analyzed using an AxoScope 10.0 system and a Digidata 1440A AC/DC converter.
Single-channel analysis of CFTR was done in the cell-attached configuration using firepolished pipettes with a resistance of 6-10 Mohm. 
RESULTS
Crofelemer inhibits Cl -secretion by T84 human intestinal epithelial cells
To test whether crofelemer reduces intestinal cell Cl -secretion, short-circuit current was measured in T84 cells in symmetrical physiological solutions (without plasma membrane permeabilization). induced by calcium agonists suggests that crofelemer inhibits both CFTR and CaCC channels, with apparently much stronger inhibition of the latter. Further measurements were done using transfected cell systems to study crofelemer effects on CFTR and CaCCs in isolation.
Though crofelemer is membrane impermeable because of its size and polarity, and thus should access only the luminal surface of intestinal epithelial cells, we investigated possible effects of basolateral application of crofelemer on apical membrane CFTR and CaCC. Studies were done in T84 cells in which 50 μM crofelemer was added to the basolateral bathing solution for 10 min prior to measurement of short-circuit current. Interestingly, though crofelemer did not affect the initial currents induced by the CFTR and CaCC agonists forskolin and ATP, respectively, crofelemer slowly reduced Cl -secretion over many minutes (Fig. 2C ). Though probably not relevant to its antidiarrheal mechanisms, crofelemer may act at the basolateral surface of T84 cells to inhibit one or more transporters involved in transepithelial Cl -secretion.
Crofelemer is a partial antagonist of CFTR Cl -conductance CFTR Cl -current was measured in CFTR-expressing FRT cells in which the basolateral membrane was permeabilized by amphotericin B and a transepithelial Cl -gradient was applied.
FRT cells were used here because they lack intrinsic chloride channel activity, form tight junctions, grow quickly, and are readily transfected with chloride channel cDNAs and reporter indicators (Verkman and Galietta, 2009) . Under these conditions the measured current provides a direct quantitative measure of CFTR Cl -conductance. Fig. 3A shows apical membrane current measurements in which CFTR Cl -conductance was stimulated by CPT-cAMP, which was followed by addition of different concentrations of crofelemer in the apical bathing solution.
Increasing concentrations of crofelemer produced notably more rapid, though partial inhibition of This article has not been copyedited and formatted. The final version may differ from this version. Measurements were done to investigate whether the crofelemer inhibition potency depends on the CFTR activation mechanism. Fig. 4A shows similar responses to 50, 200 and 500 µM crofelemer using agonists that activate CFTR directly (apigenin) or through cAMP-dependent CFTR phosphorylation (forskolin). The reversibility of crofelemer inhibition of CFTR was investigated, since washout during secretory diarrhea is a concern with use of a non-absorbable antisecretory agent. Fig. 4B shows apical current measurements in which CFTR Cl -current was stimulated by CPT-cAMP and then inhibited by different concentrations of crofelemer. Following extensive washing, residual CFTR inhibition was determined from the current after re-stimulation by CPT-cAMP. In control studies in the absence of crofelemer, washout (of CPT-cAMP) followed by re-stimulation produced a similar current to that seen in the initial stimulation. However, following inhibition with different concentrations of crofelemer washout studies showed partial (25-35 %) reversal of CFTR inhibition over 30 min. Extended time studies showed <50 % reversal of crofelemer inhibition at 4 h (not shown).
To evaluate the possibility that the site of action of crofelemer on CFTR might overlap with that of the small-molecule thiazolidinone and glycine hydrazide CFTR inhibitors, we compared CFTR inhibition in the absence and presence of pre-added crofelemer. Fig. 4C (left) shows This article has not been copyedited and formatted. The final version may differ from this version. Patch-clamp was done to investigate the molecular mechanism of CFTR inhibition by crofelemer. Whole-cell membrane current was measured in CFTR-expressing FRT cells (Fig. 5A , left). Stimulation by 10 µM forskolin produced a membrane current of 179 ± 18 pA/pF (n = 3) at +100 mV (total membrane capacitance 15.8 ± 4 pF). Crofelemer at 50 µM gave ~60 % inhibition of CFTR Cl -current. To assess single-channel CFTR properties cell-attached patch recordings were done on CFTR-expressing FRT cells in the absence or presence of crofelemer in pipette solution (Fig. 5B ).
Addition of 10 μM forskolin and 100 μM IBMX to the bath resulted in CFTR channel opening.
CFTR unitary conductance was 7.2 ± 0.1 pS (n = 4), which was not affected by crofelemer.
Crofelemer reduced channel activity remarkably, as seen by the less frequent channel openings (Fig. 5B, left) . Analysis of single-channel recordings indicated that crofelemer significantly reduced open channel probability (Po) from 0.71 ± 0.04 (n = 4) to 0.40 ± 0.04 (n = 3 Crofelemer is a strong inhibitor of the CaCC TMEM16A
The data in Fig. 2B suggested that crofelemer strongly inhibits CaCC(s) in T84 cells.
Recent work has implicated the protein TMEM16A as a CaCC in multiple epithelial cells, including intestinal epithelia, as well as in smooth muscle, nerve and other cell types (Caputo et al., 2008; Schroeder et al., 2008; Yang et al., 2008) . To test whether TMEM16A is the CaCC target of crofelemer, FRT epithelial cells stably expressing TMEM16A were pretreated with different concentrations of crofelemer, followed by addition of 1 µM ionomycin to stimulate TMEM16A Cl -current. Measurements were made in the presence of a transepithelial Cl -gradient, so that current is a direct, quantitative measure of TMEM16A Cl -conductance. Fig. 6A shows crofelemer concentration-dependent inhibition of TMEM16A Cl -current, which was nearly complete at high concentrations of crofelemer. Fig. 6B shows an IC 50 for crofelemer inhibition of TMEM16A of ~6.5 µM.
Whole-cell membrane current was measured in TMEM16A-expressing FRT cells (Fig. 6C ).
Stimulation by 100 µM ATP produced a membrane current of 56 ± 13 pA/pF (n = 3) at +100 mV.
Pretreatment with 10 µM crofelemer inhibited ATP-induced TMEM16A Cl -current by 58 % (24 ± 6 pA/pF, n = 3). Fig. 6D shows an outward rectifying current-voltage relationship for TMEM16A. Crofelemer has little effect on apical cation channels and cAMP/calcium signaling
The apical membrane of enterocytes also contains Na + and K + channels, which are potential additional targets of crofelemer. To investigate whether crofelemer alters the activity of the epithelial cell Na + channel ENaC, short-circuit current was measured in primary cultures of human bronchial epithelial cells, which robustly express ENaC and in which the change in short-circuit current following amiloride provides a quantitative measure of ENaC activity (Yamaya et al., 1994) . Fig. 7A shows that pre-treatment of the cell culture with 50 µM crofelemer produced a small, ~20 % inhibition of ENaC activity. Human bronchial epithelial cells also express TMEM16A and have robust CaCC activity. Crofelemer pre-treatment produced a >90 % reduction in short-circuit current following the addition of calcium-elevating agonist UTP, in agreement with the conclusions from T84 cells and TMEM16A-transfected FRT cells, above.
Possible inhibition of apical K + channels by crofelemer was tested in human bronchial epithelial cells in which the basolateral membrane was permeabilized with amphotericin B in the presence of a transepithelial K + gradient. Under these conditions the small measured current is an apical membrane K + current. Apical K + current was measured following addition of BaCl 2 , a nonspecific inhibitor of K + channels. Fig. 7B shows that pre-treatment with 50 µM crofelemer produced a small, ~22 % inhibition of apical membrane K + current.
Last, we tested the possibility that crofelemer action on apical membrane receptor(s) might affect major intracellular signaling pathways, which might secondarily modulate the activities of basolateral membrane transporters to inhibit transcellular Cl -secretion indirectly. Fig. 7C shows This article has not been copyedited and formatted. The final version may differ from this version. that crofelemer at 50 µM had no significant effect on basal or forskolin-stimulated cAMP concentrations in T84 cells. Fig. 7D shows that crofelemer did not alter basal cytoplasmic calcium concentration, nor did it affect the elevation in calcium concentration following ATP treatment in T84 cells.
DISCUSSION
Crofelemer is a polyphenolic molecule isolated from the latex of the plant species Croton lechleri of the family Euphorbiaceae. Crofelemer is an amorphous, dark red-brown powder consisting of an oligomeric proanthocyanidin of varying chain lengths with an average molecular weight of 2100 daltons. Crofelemer has been characterized by 1 H-NMR, The cellular antisecretory targets of crofelemer were investigated, focusing on the principal luminal membrane determinants of intestinal fluid secretion, including ion channels and signaling pathways. We found that crofelemer inhibited apical membrane cAMP-stimulated This article has not been copyedited and formatted. The final version may differ from this version. 
channel(s). Because crofelemer has minimal oral absorption, it is not expected to access the basolateral surface of enterocytes in the intestine, its action on basolateral transporter(s)
is probably not important in its antidiarrheal mechanisms.
Crofelemer acted as a partial antagonist of CFTR Cl -conductance, with a concentrationdependent rate of inhibition over several minutes. Washout of the crofelemer was slow, occurring over hours. The reason(s) are not known why, unlike thiazolidinone and glycine hydrazide CFTR inhibitors, crofelemer inhibition of CFTR Cl -conductance is partial even at very high concentrations. Some possibilities for such partial inhibition include partial external CFTR pore blockade by the large crofelemer molecule, and an intrinsically inefficient allosteric inhibition mechanism. Patch-clamp analysis indicated that crofelemer action on the extracellular-facing CFTR surface produces voltage-independent channel inhibition with stabilization of the channel closed state and without rapid channel flicker. Therefore, crofelemer inhibition of CFTR is unlikely to involve direct pore occlusion. In contrast, CFTR inhibitors of the glycine hydrazide class produced a voltage-dependent block, with inward rectification of residual CFTR Cl -current, and direct pore occlusion with rapid flicker in membrane current (Muanprasat et al., 2004; Sonawane et al., 2006 Sonawane et al., , 2007 Sonawane et al., , 2008 . The independence of crofelemer and GlyH-101 action seen in
Figs. 4C is consistent with crofelemer action at site different from that of GlyH-101, which occludes the CFTR pore. The larger molecular size of crofelemer compared to GlyH-101 is consistent with crofelemer action at a site outside of the CFTR pore. Prior studies (Gabriel et al., 1999) suggested evidence for CFTR inhibition by crofelemer in T84 cells in the presence of a large Cl -gradient. However, in the prior studies inhibition of CaCCs was not recognized nor were measurements done in a defined system where CFTR could be studied in isolation from CaCCs and other ion channels.
We discovered that crofelemer strongly inhibited CaCC(s). There is evidence, albeit indirect, suggesting that CaCCs in intestinal epithelial cells provide an important route for Cl -and fluid secretion in secretory diarrheas caused by certain drugs, including some antiretrovirals and chemotherapeutics, and some viruses (Morris et al. 1999 , Barrett, 2000 Kidd and Thorn, 2000; Takahashi et al. 2000; Gyömörey et al. 2001; Rufo et al. 2004; Thiagarajah and Verkman, 2005; Schultheiss et al. 2005 Schultheiss et al. , 2006 Farthing, 2006; Lorrot and Vasseur, 2007) . In addition to their expression in intestinal epithelial cells, CaCCs are broadly expressed in many cell types where they are involved in different functions, including transepithelial fluid secretion, olfactory and sensory signal transduction, smooth muscle contraction, and cardiac excitation (Hartzell et al., 2005; Verkman and Galietta, 2009 ). The molecular identity of CaCCs was unclear until recently, when three independent laboratories reported TMEM16A (anoctamin-1) as a CaCC (Caputo et al., 2008; Schroeder et al., 2008; Yang et al., 2008 The precise role of TMEM16A in various secretory diarrheas remains to be elucidated.
In conclusion, the cellular antisecretory action of crofelemer appears to involve two distinct 
